Atopic Dermatitis

Investigators believe that pediatric patients can gain the most from a combination of interventions, though larger studies are needed to confirm the data.

Dr. Hawryluk speaks of improving upon tolerability of existing therapies for atopic disease as well as promising new therapies on the horizon.

Dr. De Keyser highlights the success of biologics such as omalizumab and dupilumab in the treatment of asthma and atopic dermatitis in pediatric populations.

Investigators believe the reduction of DIF usage could result in cost reductions without compromising patient care.

Comprehensive discussion on how atopic dermatitis can impact a patient’s quality of life.

Considerations for persistent atopic dermatitis vs outgrowing disease, followed by triggers that can result in flare-ups.

Delgocitinib is the first and only topical JAK/STAT pathway inhibitor in Japan, and recent data suggests it is effective in the management of atopic dermatitis.

Dr. Paller speaks of the AD-GAP study, which shared insights on moderate to severe atopic dermatitis from patients, caregivers, and independent physicians.

Adult patients with moderate-to-severe atopic dermatitis reported incremental improvement of their condition in a new extension trial study presented at EADV.

Shared insight on the ways a child or adult may present with atopic dermatitis.

A panel of experts review the pathophysiology of atopic dermatitis and its contributing factors.

Additionally, investigators believe epidermal impairment in the skin of children with atopic dermatitis could contribute to the development of allergic sensitization.

Acknowledging the potential medical harm from errors and bias, investigators believe clinical AI needs to be held to a higher standard.

Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.

The drug is approved for adults and pediatric patients 12 years and older after the failure of 1 or 2 lines of systemic therapy.

The approval follows recent phase 3 trial data showing significant improvement in patient-reported outcomes for the treatment of atopic dermatitis.

Though well-tolerated and highly efficacious, the biologic was linked several adverse events in pediatric patients with atopic dermatitis including facial erythema and herpes simplex virus.

Clinical pearls regarding the management of patients with atopic dermatitis with newer treatment approaches as the field continues to evolve.

Strategies that can be used by healthcare professionals to help address patient concerns around atopic dermatitis.

Advice for healthcare professionals who treat atopic dermatitis to help them best manage patients and connect them to other supportive resources.

A new study sheds light on some of the atopic disease risks that are associated with early childhood and continue into midlife.

The importance of partnering with patients who have atopic dermatitis to best support them throughout their long-term journey with the condition.

Considerations regarding how to best select from and use newer therapies for atopic dermatitis.

Investigators push for a greater understanding of the disease in relation to the mental health of young patients, which has affected roughly 20% of the global pediatric population.

Recent phase 3 trial data confirms that dupilumab is the first biologic medicine is the first to reduce severity and symptoms of atopic dermatitis in pediatric patients.